medcura
Riverdale, US · Delaware corporation · 5 known investors
Find your way into medcura
Each arrow is one introduction. Sign up to fill in the first one.
Ask William Amsbaugh to introduce you to Larry Tiffany
You →William · together at Gene Logic →Larry
Sign up to find every way you can get introduced to medcura
- Your email: who you already know at medcura, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the medcura team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Medcura develops hemostatic products made from hydrophobically modified biopolymers to control minimal, mild, and moderate surgical bleeding through mechanical mucoadhesion. Its offerings target surgeons, patients, and payers in the surgical hemostasis market, including specialized applications such as spine surgery.
Founders & leadership




Board
Investors · 5
How we know: Aspira Capital's portfolio page · Not right? Tell us
How we know: Delaware Crossing Investor Group's portfolio page · Not right? Tell us
How we know: Maryland TEDCO's portfolio page · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$60.2M disclosed across 7 rounds · 2016–2025
▶$28.5MraisedJul 2025 · 174 investors · BiotechnologyRule 506(b)
- Rich VincentExecutive Officer
- Jim BuckDirector, Executive Officer
- Larry TiffanyDirector, Executive Officer
- Abbas Ardehali, M.D.Director
- Matthew Dowling, Ph.DDirector, Executive Officer
- Offering amount
- $38.3M
- Amount sold
- $28.5M
- Finders' fees
- $52.2K
- First sale
- Apr 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$22.5MraisedJul 2024 · 151 investors · BiotechnologyRule 506(b)
- Abbas Ardehali, M.D.Director
- Matthew Dowling, Ph.DDirector, Executive Officer
- Jim BuckDirector, Executive Officer
- Rich VincentExecutive Officer
- Larry TiffanyDirector, Executive Officer
- Offering amount
- $22.8M
- Amount sold
- $22.5M
- Sales commissions
- $119K
- First sale
- Jul 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.5MraisedNov 2021 · 45 investors · BiotechnologyRule 506(b)
- Jim BuckDirector
- Rich VincentExecutive Officer
- Matthew DowlingExecutive Officer, Director
- Larry TiffanyExecutive Officer, Director
- Offering amount
- $5.8M
- Amount sold
- $3.5M
- First sale
- Oct 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3MraisedSep 2020 · 55 investors · BiotechnologyRule 506(b)
- Matthew DowlingExecutive Officer, Director
- Alex ArrowDirector
- Larry TiffanyExecutive Officer, Director
- Jim BuckDirector
- Rich VincentExecutive Officer
- Offering amount
- $5M
- Amount sold
- $3M
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.6MraisedJul 2018 · 36 investors · BiotechnologyRule 506(b)
- Matthew DowlingExecutive Officer, Director
- Alex ArrowDirector
- Jim BuckDirector
- Larry TiffanyExecutive Officer, Director
- Offering amount
- $2.5M
- Amount sold
- $1.6M
- First sale
- Jun 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.1MraisedNov 2016 · 14 investors · BiotechnologyRule 506(b)
- Larry TiffanyDirector
- Alex ArrowDirector
- Matthew DowlingExecutive Officer, Director
- Offering amount
- $3.1M
- Amount sold
- $1.1M
- First sale
- Sep 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$11raisedApr 2016 · 1 investors · BiotechnologyRule 506(b)
- Larry TiffanyDirector
- Peter ThomasExecutive Officer, Director
- Matthew DowlingExecutive Officer, Director
- Offering amount
- $200
- Amount sold
- $11
- First sale
- Mar 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 4
Companies working in the same space as medcura.
Frequently asked questions
- What does medcura do?
- Medcura develops hemostatic products made from hydrophobically modified biopolymers to control minimal, mild, and moderate surgical bleeding through mechanical mucoadhesion. Its offerings target surgeons, patients, and payers in the surgical hemostasis market, including specialized applications such as spine surgery.
- Who are medcura's investors?
- medcura's investors include Aspira Capital, Delaware Crossing Investor Group, Maryland TEDCO, Robin Hood Ventures, TEDCO.
- How much funding has medcura raised?
- medcura has disclosed $60.2M raised across 7 rounds.
- Where is medcura headquartered?
- medcura is headquartered in Riverdale, US.





